Skip to main navigation menu Skip to main content Skip to site footer

Thromboangeitis obliterans in upperlimbs: report of a clinical case

Tromboangeítis obliteranteen extremidades superiores:reporte de un caso clínico




Section
Artículos de Reportes de Caso

How to Cite
Hernández-Navas, J. A., Resarte-Ellis, A. F., Therán-Leon, J. S. ., Dulcey-Sarmiento, L. A. ., & Gómez-Ayala, J. A. . (2025). Thromboangeitis obliterans in upperlimbs: report of a clinical case. Archivos De Medicina , 26(1). https://doi.org/10.30554/archmed.26.1.5349.2026
Download Citation

Dimensions
PlumX

How to Cite

Hernández-Navas, J. A., Resarte-Ellis, A. F., Therán-Leon, J. S. ., Dulcey-Sarmiento, L. A. ., & Gómez-Ayala, J. A. . (2025). Thromboangeitis obliterans in upperlimbs: report of a clinical case. Archivos De Medicina , 26(1). https://doi.org/10.30554/archmed.26.1.5349.2026

Download Citation

Jorge Andres Hernández-Navas
Andrés Felipe Resarte-Ellis
Juan Sebastián Therán-Leon
Luis Andrés Dulcey-Sarmiento
Jaime Alberto Gómez-Ayala

Introduction: Thromboangiitis obliterans (TAO), also known as Buerger’s disease, is
a non-atherosclerotic segmental vasculitis that primarily affects small- and mediumsized arteries and veins in the extremities. It is closely associated with tobacco consumption, which is considered the main risk factor. Although its pathogenesis is not
fully understood, the presence of macrophage and T-cell infiltration in the intraluminal
thrombus has been identified, along with increased expression of adhesion molecules
in the vascular endothelium. Case Description: We present the case of a 45-year-old
male chronic smoker who presented with ischemic pain in the lower extremities and
recurrent episodes of intermittent claudication. Clinical evaluation revealed diminished
distal pulses and trophic changes in the feet. Angiographic studies showed segmental
occlusion of the tibial arteries without evidence of atherosclerosis. A diagnosis of TAO
was established, and smoking cessation was recommended as the primary treatment,
along with vasodilator therapy and revascularization measures. Discussion: The management of TAO is based on smoking cessation, which can prevent disease progression and reduce the risk of amputation. However, in cases of critical ischemia, smoking
cessation alone may be insufficient, necessitating endovascular therapies or bypass
surgery when vascular anatomy allows. Early detection is crucial to prevent irreversible
complications. Conclusions: TAO is an underdiagnosed condition that requires a high
degree of clinical suspicion in young smokers presenting with ischemic symptoms in
the extremities. Smoking cessation remains the most effective intervention to alter the
disease course. Further research is needed to explore new therapeutic strategies to
improve prognosis in advanced cases


Article visits 16 | PDF visits 11


Downloads

Download data is not yet available.
  1. 1. Oka H, Sumitomo S, Kim K, Ohmura K. Thromboangiitis Obliterans (Buerger's Disease). QJM. 2024 Nov 14:hcae221. doi: 10.1093/qjmed/hcae221. Epub ahead of print. PMID: 39540763.
  2. 2. Chen JY. Thromboangiitis Obliterans. Anatol J Cardiol. 2021 Feb;25(2):E8. doi: 10.14744/AnatolJCardiol.2020.87425. PMID: 33583826; PMCID: PMC8114638.
  3. 3. Uyanık SA, Öğüşlü U, Aminu IS, Yılmaz B, Çevik H, Atlı E, Gümüş B. Endovascular Treatment of Critical Limb Ischemia in Buerger Disease (Thromboangiitis Obliterans) With Midterm Follow-Up: A Viable Option When Bypass Surgery Is Not Feasible. AJR Am J Roentgenol. 2021 Feb;216(2):421-427. doi: 10.2214/AJR.20.23023. Epub 2020 Dec 16. PMID: 33325735.
  4. 4. Komai H. Thromboangiitis Obliterans - A Disappearing Disease? Circ J. 2024 Feb 22;88(3):329-330. doi: 10.1253/circj.CJ-23-0524. Epub 2023 Aug 21. PMID: 37599078.
  5. 1. Chapman S, Ballinger K, Chan MK, Stefanovici C, Rozovsky K, Boyd A, et al. Thromboangiitis Obliterans (Buerger’s Disease) in an Adolescent Male. J Pediatr Hematol Oncol [Internet]. 2021 Aug 1 [cited 2025 Feb 25];43(6):E759–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32925405/
  6. 2. Chapman S, Ballinger K, Chan MK, Stefanovici C, Rozovsky K, Boyd A, et al. Thromboangiitis Obliterans (Buerger’s Disease) in an Adolescent Male. J Pediatr Hematol Oncol [Internet]. 2021 Aug 1 [cited 2025 Feb 25];43(6):E759–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32925405/
  7. 3. Chapman S, Ballinger K, Chan MK, Stefanovici C, Rozovsky K, Boyd A, et al. Thromboangiitis Obliterans (Buerger’s Disease) in an Adolescent Male. J Pediatr Hematol Oncol [Internet]. 2021 Aug 1 [cited 2025 Feb 25];43(6):E759–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32925405/
  8. 4. Chapman S, Ballinger K, Chan MK, Stefanovici C, Rozovsky K, Boyd A, et al. Thromboangiitis Obliterans (Buerger’s Disease) in an Adolescent Male. J Pediatr Hematol Oncol [Internet]. 2021 Aug 1 [cited 2025 Feb 25];43(6):E759–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32925405/
  9. 5. Chapman S, Ballinger K, Chan MK, Stefanovici C, Rozovsky K, Boyd A, et al. Thromboangiitis Obliterans (Buerger’s Disease) in an Adolescent Male. J Pediatr Hematol Oncol [Internet]. 2021 Aug 1 [cited 2025 Feb 25];43(6):E759–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32925405/
  10. 6. Chapman S, Ballinger K, Chan MK, Stefanovici C, Rozovsky K, Boyd A, et al. Thromboangiitis Obliterans (Buerger’s Disease) in an Adolescent Male. J Pediatr Hematol Oncol [Internet]. 2021 Aug 1 [cited 2025 Feb 25];43(6):E759–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32925405/